BR112020006189A2 - conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas - Google Patents
conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas Download PDFInfo
- Publication number
- BR112020006189A2 BR112020006189A2 BR112020006189-1A BR112020006189A BR112020006189A2 BR 112020006189 A2 BR112020006189 A2 BR 112020006189A2 BR 112020006189 A BR112020006189 A BR 112020006189A BR 112020006189 A2 BR112020006189 A2 BR 112020006189A2
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- derivative
- lysine
- conjugate
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126577 | 2017-09-28 | ||
| KR10-2017-0126577 | 2017-09-28 | ||
| PCT/KR2018/011586 WO2019066586A1 (ko) | 2017-09-28 | 2018-09-28 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020006189A2 true BR112020006189A2 (pt) | 2020-10-13 |
Family
ID=65902619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020006189-1A BR112020006189A2 (pt) | 2017-09-28 | 2018-09-28 | conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11530249B2 (https=) |
| EP (1) | EP3689898B1 (https=) |
| JP (2) | JP7751381B2 (https=) |
| KR (2) | KR102681143B1 (https=) |
| CN (1) | CN111433221B (https=) |
| AR (1) | AR113258A1 (https=) |
| AU (1) | AU2018339210B2 (https=) |
| BR (1) | BR112020006189A2 (https=) |
| CA (1) | CA3084326A1 (https=) |
| EA (1) | EA202090571A1 (https=) |
| IL (1) | IL273528B2 (https=) |
| MX (1) | MX2020004453A (https=) |
| PH (1) | PH12020550105A1 (https=) |
| SA (1) | SA520411644B1 (https=) |
| SG (1) | SG11202002563WA (https=) |
| TW (2) | TWI795443B (https=) |
| WO (1) | WO2019066586A1 (https=) |
| ZA (1) | ZA202001888B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| JP7846622B2 (ja) * | 2019-12-24 | 2026-04-15 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物 |
| EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| WO2021201654A1 (ko) | 2020-04-03 | 2021-10-07 | 한미약품 주식회사 | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 |
| MX2022014671A (es) * | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de conjugado de glp-2 de accion prolongada. |
| BR112022025141A2 (pt) | 2020-06-09 | 2023-04-25 | Vectivbio Ag | Fabricação, formulação e dosagem de apraglutida |
| KR20220092446A (ko) * | 2020-12-24 | 2022-07-01 | 한미약품 주식회사 | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 |
| JP2025513345A (ja) * | 2022-04-18 | 2025-04-24 | ハンミ ファーマシューティカル カンパニー リミテッド | 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法 |
| CN120435309A (zh) | 2022-12-23 | 2025-08-05 | 韩美药品株式会社 | 含有glp-2衍生物或其长效缀合物的用于预防或治疗移植物抗宿主病的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| DK1360202T3 (da) * | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| HRP20060362A2 (en) * | 2004-04-23 | 2007-03-31 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| UA95235C2 (en) * | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
| JP6206972B2 (ja) * | 2011-09-12 | 2017-10-04 | アムニクス オペレーティング インコーポレイテッド | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
| KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
-
2018
- 2018-09-28 EA EA202090571A patent/EA202090571A1/ru unknown
- 2018-09-28 SG SG11202002563WA patent/SG11202002563WA/en unknown
- 2018-09-28 AR ARP180102806A patent/AR113258A1/es unknown
- 2018-09-28 BR BR112020006189-1A patent/BR112020006189A2/pt unknown
- 2018-09-28 IL IL273528A patent/IL273528B2/en unknown
- 2018-09-28 EP EP18860379.9A patent/EP3689898B1/en active Active
- 2018-09-28 CN CN201880074180.4A patent/CN111433221B/zh active Active
- 2018-09-28 TW TW107134398A patent/TWI795443B/zh active
- 2018-09-28 MX MX2020004453A patent/MX2020004453A/es unknown
- 2018-09-28 KR KR1020180116327A patent/KR102681143B1/ko active Active
- 2018-09-28 WO PCT/KR2018/011586 patent/WO2019066586A1/ko not_active Ceased
- 2018-09-28 TW TW110126453A patent/TWI794897B/zh active
- 2018-09-28 CA CA3084326A patent/CA3084326A1/en active Pending
- 2018-09-28 JP JP2020517828A patent/JP7751381B2/ja active Active
- 2018-09-28 AU AU2018339210A patent/AU2018339210B2/en active Active
-
2020
- 2020-03-19 PH PH12020550105A patent/PH12020550105A1/en unknown
- 2020-03-24 ZA ZA2020/01888A patent/ZA202001888B/en unknown
- 2020-03-27 US US16/832,634 patent/US11530249B2/en active Active
- 2020-03-28 SA SA520411644A patent/SA520411644B1/ar unknown
-
2022
- 2022-04-14 US US17/721,048 patent/US20220251164A1/en active Pending
- 2022-11-02 US US17/979,531 patent/US20230090790A1/en active Pending
-
2023
- 2023-07-06 JP JP2023111438A patent/JP2023138505A/ja active Pending
-
2024
- 2024-01-22 KR KR1020240009740A patent/KR102681144B1/ko active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11530249B2 (en) | Long-acting conjugates of GLP-2 derivatives | |
| ES2802099T3 (es) | Una composición para el tratamiento de la diabetes que comprende un análogo de oxintomodulina | |
| TWI708782B (zh) | 新穎胰島素類似物及其用途 | |
| ES2842881T3 (es) | Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina | |
| ES2882520T3 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina y su uso | |
| ES2897732T3 (es) | Composición para tratar la diabetes mellitus que comprende insulina y un agonista doble de glp-1/glucagón | |
| KR20200095436A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
| CN110536899B (zh) | 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途 | |
| US20220064248A1 (en) | Pharmaceutical composition including insulin and glucagon | |
| HK40024582A (en) | Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative | |
| EA047924B1 (ru) | Конъюгаты производных glp-2 пролонгированного действия | |
| KR20210144609A (ko) | 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제 | |
| KR20230095666A (ko) | 간 표적 물질 및 이의 용도 | |
| BR112016028076B1 (pt) | Composição para o tratamento de diabetes mellittus que compreende insulina e um agonista dual glp-1/glucagon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |